Initial Results From A Phase 1 Study of CFT8634, A Novel Bifunctional Degradation Activating Compound of BRD9, in Synovial Sarcoma and SMARCB1-Null Tumors .
Silas Inman joined MJH Life Sciences® in early 2011 as one of the company's first web editors, on the website OncLive.com. Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. In 2014, he integrated CURE® Media Group into the MJH portfolio, quickly growing the online traffic, launching new offerings, and streamlining the brand’s print strategy. He continued this trend in 2019 with the acquisition of the UBM Life Sciences brands, which includes brands such as Medical Economics®.
Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
/PRNewswire/ The Institute for Myeloma & Bone Cancer Research (IMBCR) announces the publication in Targeted Oncology on the outstanding survival of 161.